Are current antibody discovery platforms and screening strategies meeting our expectations for effective lead identification?

Which emerging platforms and methodologies show promise in streamlining antibody triage for bispecific T-cell engagers?

What steps can we take to shorten the timeline for candidate selection process in the ADC or AOC development pipeline?